YOLFTbeta
Marvel Biosciences Corp

Marvel Biosciences Corp

MRVL · V · Healthcare / Biotechnology

0.13CAD+0.01 (+4.00%)

Price History

Full chart

Market Stats

Previous Close0.125
Open0.13
Day Range0.13 – 0.13
52-Week Range0.105 – 0.25
Volume12.73K
Market Cap8.84M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.03
Dividend Yield0.00%
Beta0.58
50-Day Avg0.1546
200-Day Avg0.1545

About

Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company's lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer's disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hallucinogenic neuroplasticity program. The company is headquartered in Calgary, Canada.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. J. Roderick Matheson
  • Employees0
  • Headquarters505 8th Avenue S.W., Calgary, AB, Canada, T2P 1G2, Canada
  • Websitehttps://marvelbiotechnology.com

Leadership

  • Mr. J. Roderick MathesonExecutive Chairman & CEO
  • Dr. Mark Williams M.B.A., Ph.D.President, Chief Science Officer & Director · b. 1972
  • Mr. Harpreet Nijjar C.M.A., CPAChief Financial Officer · b. 1988
  • Ms. Jacqueline GrootCorporate Secretary

Financials

Income Statement

Currency: CAD2019-07-312020-07-312021-07-312022-07-312023-07-312024-07-312025-07-31
Total Revenue-000000
Cost of Revenue-265.20K613.10K1.38M887.52K302.02K547.37K
Gross Profit--265.20K-613.10K-1.38M-887.52K-302.02K-547.37K
Operating Expense-689.57K485.04K1.17M1.36M969.86K701.32K
Operating Income--954.77K-1.10M-2.55M-2.25M-1.27M-1.25M
EBITDA--954.36K-1.10M-2.55M-2.26M-1.54M-1.94M
Net Income--955.66K-3.04M-2.55M-2.29M-1.65M-2.21M
R&D---1.38M887.52K302.02K547.37K
Interest Expense000038.42K113.98K268.01K

Balance Sheet

Currency: CAD2019-07-312020-07-312021-07-312022-07-312023-07-312024-07-312025-07-31
Total Assets-295.99K2.47M913.54K672.39K491.31K326.71K
Total Liabilities-177.18K112.48K718.00K2.39M3.32M4.33M
Total Equity-118.80K2.36M195.54K-1.72M-2.83M-4.01M
Cash-224.81K2.39M593.21K556.62K345.77K128.85K
Net Debt----443.38K1.36M2.18M

Cash Flow

Currency: CAD2019-07-312020-07-312021-07-312022-07-312023-07-312024-07-312025-07-31
Operating Cash Flow-157.41K-538.53K-1.37M-2.19M-1.33M-1.18M-1.15M
Investing Cash Flow-1.03K381.57K381.57K----
Financing Cash Flow158.61K763.17K3.16M394.00K1.30M968.64K933.41K
Capital Expenditure1.03K000000
Free Cash Flow--538.53K-1.37M-2.19M-1.33M-1.18M-1.15M
FCF to OCF-100.00%100.00%100.00%100.00%100.00%100.00%

Earnings

Report DateNov 26, 2026
EPS Estimate-
EPS Actual-
Surprise-
TimingAfter-hours

Key Statistics & Ratios

Market Cap8.84M
Enterprise Value10.42M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book226.82
EPS-0.03
Book Value-0.043
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-2.19M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-380.30%
Return on Assets-172.06%
Shares Outstanding73.68M
Shares Float49.40M
Beta0.58
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%